ABOUT US

About Us

Development History

2019–Present >>> The Moment of Breakthrough

The cumulative number of projects undertaken has exceeded 500. Over 60% of the projects are innovative drug programs. There are more than 10 cell therapy projects. Acquired Suhao Bio (biomaterials for tissue regeneration).

2015-2018 >>> The Period of Running

Established separate subsidiaries for pharmaceutical CRO, medical device CRO, and SMO services. Secured capital investment of 25 million yuan. Obtained 9 pharmaceutical invention patents and 6 software copyrights. Rare disease therapeutic drugs approved for conditional marketing. Undertook a key national R&D project under the 13th Five-Year Plan.

2011-2014>>> The Turning Point

Expand the medical device CRO business Establishment of a Regenerative Medicine R&D Center Innovative service capabilities are at the forefront of the industry.

2006-2010>>> Early Stages

A CRO company was founded, offering import registration and clinical services. Established partnerships with Fortune 100 multinational pharmaceutical companies, including Pierre Fabre. Completed 8 import registration and clinical projects.